Press Release: SWK : pSivida Corp. Announces Transformative Acquisition of Icon Bioscience Inc. and Growth Capital Financing with Essex Woodlands Healthcare Partners - Company Will Rebrand as EyePoint Pharmaceuticals, Inc.

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the acquisition of Icon Bioscience Inc. (Icon). Icon is a specialty biopharmaceutical company whose lead product DEXYCU (dexamethasone intraocular suspension) 9% is FDA approved for postoperative inflammation and is administered as a single dose at the end of ocular surgery. DEXYCU is the first long-acting intraocular product approved by the FDA for the treatment of postoperative inflammation. DEXYCU utilizes Icon’s proprietary Verisome® drug-delivery platform which allows for a single injection that releases over time.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
CEO Avatar


Winston Black

CEO Approval Rating


SWK is a finance company that provides capital to a range of life science companies, institutions and inventors. Read more